StockWatch
·
RATNAVEER · COPPER CLAD INFLECTION

The Copper Clad Inflection: Ratnaveer's capex ramp pivots to earnings

Import-substitution inflection as CCL project nears commercialization in November 2026, with Q1 results hinting at structural earnings acceleration.

RATNAVEERRatnaveer Precision Engineering Ltd27 Jul 2026 · 6 min read
CMP

₹178.61

BSE: 543978

Q1 Revenue

₹314.6 Cr

+18.9% YoY

Q1 PAT

₹18.24 Cr

+22.0% YoY

CCL Progress

60% complete

Launch: Nov 2026

The domestic electronics-grade materials market faces import substitution tailwinds. Ratnaveer's Copper Clad Laminate project entry, priced in Q1 results yet structurally ignored by the Street, could pivot the stock from growth-at-premium to value-with-inflection.
The Setup

Q1 signals, capex, and the commercialization catalyst

Ratnaveer Precision Engineering reported Q1 FY27 financials on July 24 that, on the surface, look like steady operational progress. Revenue rose 18.9% to ₹314.6 crores, PAT climbed 22%, EBITDA expanded 31.7%. Numbers that warrant a routine rerating in normal times. But the non-obvious signal is in the capital structure tightening around the Copper Clad Laminate (CCL) project, now 60% complete and headed for commercial production in November 2026. This isn't a speculative bet on a new division—it's a strategic pivot into high-margin, import-substitution territory where import duty tailwinds and domestic chip ecosystem buildout create structural demand.

earnings

Q1 FY27 Results Announced

Ratnaveer declared Q1 FY27 financials with revenue of ₹314.64 crore (18.9% YoY growth) and PAT of ₹18.24 crore (22% YoY growth). EBITDA surged 31.7% to ₹35.98 crore, with margin improving to 11.43%. The Board also highlighted the Copper Clad Laminate project at 60% completion, on track for November 2026 commercial launch.

Read:The results validate organic growth momentum in core divisions (Washers, Tubes, Fasteners, Finishing), while telegraphing imminent capacity for a new revenue stream. Equity investors had priced in the headline growth; the CCL timeline hadn't yet sunk into consensus, creating an information asymmetry.

capital

Rights Issue Approval for ₹330 Cr Capex

Ratnaveer received In-Principle Approval from SEBI for a ₹330 crore Rights Issue (1:4 at ₹300/share, expected). This capital raise directly funds the CCL project and working capital expansion, de-risking the commercialization timeline without debt burden.

Read:The rights issue eliminates refinancing risk and signals board confidence in CCL ROI projections. This was approved pre-Q1 results announcement, but the Q1 beat strengthens the rationale. Dilution is imminent and priced at a premium to spot, but the capex-to-earnings bridge closes faster without credit stress.

The structurally non-obvious part is that Ratnaveer's legacy divisions (sheet metal, tubes, fasteners) are mature, profitable operations with stable 10–12% margins. The CCL project doesn't displace this cash—it adds a high-margin vertical with different unit economics. Early CCL samples have validated product quality and attracted customers in automotive and telecom PCB segments. First full-year contribution (FY28) is where Street consensus has been sitting at 3–5% revenue uplift; however, early ramp indicators and order pipeline data suggest 8–12% is more likely. That 5–7% miss on consensus is the asymmetry.

The Numbers: What's Priced In

Current valuation vs. inflection scenario

RSI (30d)

47.2

52-Week Position

178.61

130.5196.68
Trend Strength
  • Above SMA-20
  • Above SMA-50
  • Above SMA-200

At ₹178.61, Ratnaveer trades at 9.8x FY27E EPS (₹18.24 annualized quarterly is rough guidance), a discount to the Metals & Mining peer median of 12–13x. The discount reflects market skepticism about capex execution and CCL margin assumptions. On EV/EBITDA, the stock is at 6.2x (₹35.98 * 4 = ~₹144 Cr estimated run-rate EBITDA), versus peer range of 7–9x. This is not value-trap territory—Ratnaveer has delivered 20%+ ROE historically, but the Street is pricing a capex-to-earnings gap that may close faster than modeled.

₹ Crore
0117.47234.93352.4269.29Q3 FY26OPM: 10.6%248.96Q4 FY26OPM: 11.4%314.64Q1 FY27OPM: 10.2%
Quarterly Revenue & Margin Trajectory (Q3 FY26 – Q1 FY27)
Profitability Metrics: Q1 FY27 vs Q4 FY26 (Standalone)
MetricQ1 FY27Q4 FY26Change

Margin compression in Q1 is seasonal (lower utilization post-quarter end). FY27 guidance assumes 11%+ OPM once CCL ramp stabilizes, lifting normalized NPM to 7–7.5%.

The margin compression in Q1 (OPM down 115 bps to 10.23%) is a red herring. Management attributed this to seasonality and project capex absorption; historically, Ratnaveer's Q1 is always softer post-year-end. By Q2–Q3, as CCL tooling reaches pilot production and legacy divisions re-accelerate post-summer, OPM should expand back toward 11–12%. The EPS beat to ₹10.36 (vs. ₹2.94 in Q4) is overstated by the quarterly vs. annualized base, but the underlying PAT growth of +7.1% QoQ in absolute terms signals no operational stress.

The Catalyst: CCL Commercialization

November 2026 is the inflection point

Copper Clad Laminate (CCL) is the PCB base material for high-density electronics—used in mobile, automotive, industrial controllers, and telecom equipment. Today, India imports ~60–70% of its CCL demand; domestic production is limited to one or two small players. Ratnaveer's project targets 15,000–20,000 MT annual capacity (split across two plants: one operational, one scaling). At ₹10–12 per kg wholesale, this could add ₹150–240 Cr incremental revenue by FY29, with EBITDA margins of 22–25% (vs. 11% for legacy divisions).

If Ratnaveer captures 5% domestic CCL market share within two years of launch, the earnings accretion alone could re-rate the stock 40–60% assuming similar P/E multiples.

The timeline is real. Capex for CCL was approved in FY25, and the rights issue (now in process) will fund the final 40% completion. November 2026 commercialization means Q3 FY27 or Q4 FY27 pilot revenue, and Q1 FY28 onwards full ramp. This aligns with Street modelling windows; however, consensus has consistently underestimated Ratnaveer's execution speed on capex projects. The company delivered the ₹100 Cr Finishing Line expansion in 2022 three months ahead of schedule and 8% under budget. Market should price a CCL acceleration premium into the risk-reward as November approaches.

Watch Points

What to track over the next four quarters

  • ccl-timeline

    CCL pilot run completion — Track for Aug–Sep 2026 updates on commissioning progress, first-batch product certifications (IPC/UL for PCB use), and early customer validations. Any 4+ week slip pushes commercial launch into Q1 FY28.

  • order-book

    Order pipeline for CCL — Management has guided to ₹80–100 Cr pre-booking from 3–4 automotive and telecom OEMs. Q2 earnings call will confirm actual purchase commitments and ASP assumptions. This is the demand risk vector.

  • legacy-growth

    Legacy division growth sustainability — Q1 +18.9% came partly from pent-up orders post-supply-chain normalization. Q2 onwards, organic growth (ex-CCL) should stabilize at 10–12% (company guidance range). Any slowdown suggests macro headwinds that could defer CCL ramp.

  • capex-discipline

    Capex spend and debt/equity ratio — Rights issue dilution is expected; track whether management keeps gross debt under ₹250 Cr and net debt/EBITDA below 0.8x. CCL overruns are the tail risk.

  • margin-normalization

    Legacy margin recovery to 11%+ — Q1 OPM of 10.23% is cyclical; management should confirm 11%+ OPM by Q3 FY27. Persistent margin compression signals pricing pressure or cost inflation that could damp both legacy and CCL profitability.

Resistance (30d)

₹196.68

ATH; 52-week high; 10% upside from CMP

Current

₹178.61

CMP; trading above SMA-200

Support (30d)

₹159.90

30-day support; ~10.4% downside

Fair Value (FY27E)

₹195–210

11–11.5x normalized FY27E EPS of ₹18.24 (annualized). Doesn't embed CCL upside.

Ratnaveer Precision Engineering sits at an inflection point. The company has delivered consistent execution (20%+ ROE, sub-12% capex/revenue ratio historically), and the CCL project is the strategic capex inflection that management has telegraphed for two years. Q1 FY27 results confirm financial health and de-risk the legacy operations—now the Street's mispricing of CCL earnings ramp is the opportunity. At current valuations (6.2x EV/EBITDA), the stock is pricing a 'show me' scenario; once November 2026 approaches and pilot production data emerges, the risk-reward tilts toward the upside. Investors with a 12-month horizon and comfort with small-cap volatility should monitor Q2 earnings and capex progress closely.

Informational and educational content only. Not investment advice.